18 February 2013 |
SAREUM HOLDINGS PLC
(“Sareum” or “the Company”)
HALF-YEARLY RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2012
Sareum (AIM: SAR), the specialist cancer drug discovery business, is pleased to announce its half-yearly results for the six month period ended 31 December 2012.
Financial highlights
Operational highlights
Dr Tim Mitchell, CEO of Sareum Holdings plc, said: “We are pleased with progress and our confidence in our ability to exploit our research programmes commercially remains high. A key commercial goal remains to enter into profitable licensing arrangements but only when they represent a good return for shareholders. We continue to take in-house programmes forward by building more comprehensive pre-clinical dossiers and as appropriate moving forward into pre-clinical toxicology studies and ultimately Phase I clinical trials.”
Sareum Holdings plc |
|
Tim Mitchell, Chief Executive Officer |
01223 497 700 |
|
|
Merchant Securities Limited (NOMAD) |
|
Simon Clements |
020 7628 2200 |
|
|
Hybridan LLP (Broker) |
|
Claire Noyce / Deepak Reddy |
020 7947 4350 |
|
|
The Communications Portfolio (Media enquiries) |
|
Philip Ranger / Caolan Mahon
|
020 7536 2028 / 2029 |
The full report is avaialble as a pdf document: Financial Results for the Six Months Ended 31/12/12